GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...
GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands ...
Two former Pfizer executives said they will not be involved with activist investor Starboard Value, which reportedly wants ...